Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FedEx Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $298.83 (market cap $39.89B), while FedEx Corporation trades at $314.69 (market cap $75.09B). The key difference: FedEx Corporation is the larger of the two by market cap, and FedEx Corporation pays a 1.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FDX | |
|---|---|---|
Market Cap | $39.89B | $75.09B |
Sector | Health | Industrials |
52-Week High | $491.22 | $338.75 |
52-Week Low | $278.09 | $174.81 |
Enterprise Value | $38.15B | $104.72B |
Dividend Yield | — | 1.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FedEx (FDX) trades at $314.69, up 1.24% on the day, with a bearish technical signal from moving averages but oversold RSI levels. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.31 exceeding expectations. The company is executing strategic moves, including the sale of its supply chain unit to CMA CGM for $1.4 billion and a $4.15 billion debt tender offer to reduce leverage. Fundamentals show stable revenue near $88 billion and a net income margin of 4.68%, though operating cash flow declined to $7.04 billion in 2025.
The outlook is mixed; analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain amid competitive pressures from Amazon Logistics. Risks include soft shipping demand and ongoing cost-cutting needs. The stock offers value with a P/E of 16.97, but investors should monitor execution of efficiency initiatives and freight segment performance post-spinoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
